Cargando…
Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM)
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315257/ http://dx.doi.org/10.1186/1479-5876-13-S1-K8 |
| _version_ | 1782355446864019456 |
|---|---|
| author | Puzanov, Igor |
| author_facet | Puzanov, Igor |
| author_sort | Puzanov, Igor |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4315257 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-43152572015-02-12 Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM) Puzanov, Igor J Transl Med Keynote Speaker Presentation BioMed Central 2015-01-15 /pmc/articles/PMC4315257/ http://dx.doi.org/10.1186/1479-5876-13-S1-K8 Text en Copyright © 2015 Puzanov; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Keynote Speaker Presentation Puzanov, Igor Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM) |
| title | Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM) |
| title_full | Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM) |
| title_fullStr | Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM) |
| title_full_unstemmed | Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM) |
| title_short | Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM) |
| title_sort | combining targeted and immunotherapy: braf inhibitor dabrafenib (d) ± the mek inhibitor trametinib (t) in combination with ipilimumab (ipi) for v600e/k mutation-positive unresectable or metastatic melanoma (mm) |
| topic | Keynote Speaker Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315257/ http://dx.doi.org/10.1186/1479-5876-13-S1-K8 |
| work_keys_str_mv | AT puzanovigor combiningtargetedandimmunotherapybrafinhibitordabrafenibdthemekinhibitortrametinibtincombinationwithipilimumabipiforv600ekmutationpositiveunresectableormetastaticmelanomamm |